What is the recommended dosage for Bifidobacterium breve?

General: 1-10 billion CFU/day; Adult Gi Support: 5-10 billion CFU/day; Neonatal Support: 1-5 billion CFU/day (as directed by pediatrician)

What are the side effects of Bifidobacterium breve?

Potential side effects include: Mild gas during initial use, Occasional loose stools in infants (transient), Rare abdominal discomfort, Very rare: bacteremia in immunocompromised individuals.

What is Bifidobacterium breve and how does it work for gut health?

Bifidobacterium breve is a probiotic species commonly found in the infant gut and breast milk. It ferments a wide variety of sugars and produces acetic and lactic acid, helping to lower intestinal pH and inhibit pathogenic bacteria. Research suggests it may support digestive comfort and help modulate immune responses in the gut-associated lymphoid tissue.

What is the recommended dosage of Bifidobacterium breve?

Studies have used dosages of 1 billion to 100 billion CFU per day depending on the condition and formulation. A common effective dose in clinical trials is 5-10 billion CFU daily. The strain B. breve Yakult (BBG-01) and B. breve M-16V are among the most studied strains with specific dosing protocols.

Are there side effects or interactions with Bifidobacterium breve?

Bifidobacterium breve is considered very safe, even in vulnerable populations such as infants and elderly individuals. Side effects are rare and typically limited to mild, transient digestive symptoms. No significant drug interactions have been documented, though individuals on immunosuppressive therapy should consult their doctor before use.

Bifidobacterium breve
Bifidobacterium breve

probiotic_strain

Também conhecido como: B. breve, Yakult, M-16V, BR03

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dbifidobacterium\u002Dbreve'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

About

Bifidobacterium breve is one of the earliest colonizers of the infant gut and plays a key role in neonatal intestinal health. It produces conjugated linoleic acid with anti-inflammatory properties and may help competitively exclude pathogens from the intestinal lining. Research suggests it may support intestinal barrier function, particularly in the developing gut.

How It Works

Produces conjugated linoleic acid (CLA) with anti-inflammatory effects on intestinal mucosa; competitively excludes pathogens from epithelial binding sites; modulates intestinal permeability in neonates by enhancing tight junction protein expression; ferments human milk oligosaccharides promoting infant gut colonization.

Evidence For Conditions

Condição	Nota	Estudos	Participantes
Irritable Bowel Syndrome (IBS)	D	2	150	Ver →

Side Effects

Mild gas during initial use
Occasional loose stools in infants (transient)
Rare abdominal discomfort
Very rare: bacteremia in immunocompromised individuals

Drug & Supplement Interactions

Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
Immunosuppressants (use with caution in immunocompromised patients)

Informe sempre o seu profissional de saúde sobre todos os suplementos que você toma.Sempre informe seu profissional de saúde sobre todos os suplementos que você toma.

Related Ingredients

Lactobacillus gasseri Lactobacillus casei Lactobacillus rhamnosus GG Saccharomyces boulardii Bifidobacterium longum

Dados Rápidos

Dosagem: General: 1-10 billion CFU/day; Adult_Gi_Support: 5-10 billion CFU/day; Neonatal_Support: 1-5 billion CFU/day (as directed by pediatrician)
Formas: powder drops (liquid) capsule sachet
Fontes Naturais: Breast milk, Infant GI tract (dominant in neonates), Fermented dairy products
Limite Superior: Well-tolerated up to 10 billion CFU/day in clinical trials
Melhor Horário: Before meals or on empty stomach; for infants, mix with breast milk or formula

Resumo das Evidências

Irritable Bowel Syndrome (IBS) D

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.